Home

Featured Profile

Health Advance Inc HADV HADV $HADV

Health Advance, Inc. (OTCQB: HADV profiled @ $0.07) is a publicly held Wyoming corporation operating as a distributor of cost-effective conventional pharmaceutical products and GRAS (Generally Referred to as Safe) regulated medical foods that contain botanical extract blends in efforts to treat cancer, epilepsy, PTSD, and other severe illnesses, working in cooperation with international dietary supplement and pharmaceutical developers.

Watch Health Advance Inc
(OTC: HADV) Brief Company Overview

Health Advance, Inc. is dedicated to providing value through quality, innovation, development, and growth of pharmaceutical products derived from an integration of organic and conventional product formulations. Our mission is to improve patient health, provide clinical practices with diversified therapeutic treatment options, and reduce the cost of harmful side effects of drugs on the healthcare system. Health Advance corporate website is HADVInc.com owns and operates HantianLabs.com, LeadingMedicalProducts.com, and BestTamanuOil.com.

Health Advance, Inc. is dedicated to providing value through quality, innovation, development, and growth of  pharmaceutical products derived from an integration of organic and conventional product formulations. Our mission is to improve patient health, provide clinical practices with diversified therapeutic treatment options, and reduce the cost of harmful side effects of drugs on the healthcare system.

Cebidiofen

Cebidiofen is a provisional patent pending, product formulations (USPTO Patent Pending Application No. 62464442) for a pharmaceutical food made from Ibuprofen and a botanical extract blends containing cannabidiol and kava tied to the production of the neurotransmitters that enable management and enhancement to sensory response to pain and inflammation, formulated by ingredients that are classified as Generally Recognized as Safe (GRAS) by the American Food and Drug Administration (FDA).

Polyoxyfen

Polyoxyfen is a provisional patent pending, product formulations (USPTO Patent Pending Application No. 62464423) for a pharmaceutical food made from Ibuprofen and a botanical extract blends containing mitragyna speciose tied to the production of the neurotransmitters that enable management and enhancement to sensory response to pain and inflammation, formulated by ingredients that are classified as Generally Recognized as Safe (GRAS) by the American Food and Drug Administration (FDA).Current Research Pipeline.

Our acquisition in North America of two patent pending product formulations, cebidiofen and polyoxyfen, in partnership with Micro Medtech, Ltd. have entered a phase two, product development plan with Nutrasource Diagnostics, Inc. for medical foods that meet Generally Recognized As Safe (GRAS) regulatory standards; a pipeline process that is planned to complete in June 2017.

Welcome to The OTC Report

TheOTCReport.us  we strive to bring our knowledge of the marketplace and explosive growth opportunities directly to our qualified subscribers. By exploring companies that have yet to receive any major market exposure, our clients can position themselves before a market upsurge occurs allowing for a profitable entry into an equity.

Our strength lies in finding these undervalued and under-marketed companies and delivering our research to our clients. That’s our goal. That’s what we do. We are “the word on the street”.

“200{8196ffbc55cf07637c162ffac099fb2975ca9a8494c3941b5af7db5d86971045} returns in less than a month? I am sure we have all heard that before from a friend or colleague who invested in a stock and made the right choices at the right time and wished  we had done the same. Now imagine if we could do that over and over again…

Please visit the other links to find out more about TheOTCReport.us and how you can benefit from our service.

Experience Matters

TheOTCReport’s public relations, communications, and marketing pros will prepare accurate and consistent communications plans that shareholders love.